BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

ADRs added ~2% in the premarket on Monday after the German vaccine maker exceeded Street forecasts with its Q2 2025 financials, thanks mainly to an over two-fold rise in its revenue. The maker of the ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6% higher at $102.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89) per share ...

If an investor was to purchase shares of BNTX stock at the current price level of $155.86/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...